AI evidence synthesis service that delivers pharma R&D decision packages on indication, target, biomarker, and trial design in days.
Quinn is a Stanford spinout backed by Y Combinator that synthesizes biological, clinical, and competitive evidence from public sources or proprietary data to produce structured decision-ready outputs in 2-5 days. Services cover indication prioritization, target and modality assessment, biomarker and patient selection, clinical trial design, and target discovery. Outputs include traceable evidence packages, reproducible code, and validation protocols; the platform is SOC 2 Type II, ISO 27001, and HIPAA compliant with 100% client IP ownership. Quinn is a product of Quinn.